Ixekizumab, a drug being evaluated for the treatment of moderate-to-severe chronic plaque psoriasis, continues to demonstrate efficacy and safety in Phase III trials.
Patients treated with certolizumab pegol for 24 weeks showed rapid improvement in the signs and symptoms of psoriatic arthritis.
The National Psoriasis Foundation (NPF) recently announced a number of new programs and a five-year strategic mission for the organization with initiatives that are designed to increase research and uncover new treatments for all forms of psoriasis and psoriatic disease.
When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.
The National Psoriasis Foundation (NPF) announced in a press release that the Centers for Medicare and Medicaid Services will not cut reimbursement for phototherapy in 2015.
Many studies that inform current international guidelines for the treatment of psoriatic arthritis (PsA) are of poor quality and lack applicability in clinical practice.